DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
NHLBI Annual Sickle Cell Disease Research Meeting
The National Heart, Lung, and Blood Institute (NHLBI) under the National Institutes of Health (NIH) is set to host the 2023 NHLBI Annual Sickle Cell Disease Research Meeting. The 3-day meeting will commence on August 14, 2023, at 9:00 am EDT and will come to a close on Wednesday, August 16 at 5:00 pm. The conference offers a platform for researchers, health care providers, and other stakeholders who are interested in sickle cell disease to discuss ongoing research, new developments in scientific and clinical aspects of sickle cell disease, and progress updates. The meeting will also provide an opportunity for investigators to interact with other researchers and NHLBI program staff.


Related Content
-
news & eventsGlycoMimetics Announces Pricing of Public Offering of Common StockGlycoMimetics, Inc. (NASDAQ: GLYC), a cl...
-
people & placesJohn T. Horan MD, MPHJohn T. Horan, MD, MPH, is Associate Pro...
-
people & placesMark C. Walters, MDDr. Walters is the director of Bone Marr...
-
education & researchHealthcare Providers and Sickle Cell DiseaseSickle cell disease (SCD) is a group of ...
-
education & researchPerioperative considerations for patients with sickle cell disease: a narrative reviewPURPOSE: Approximately 200,000 individua...
-
news & eventsEmmaus Life Sciences, Inc. to present results of phase 3 study of endariTM (L-glutamine oral powder) at 59th America...Emmaus will present results of a Phase 3...
-
news & events
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by

This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.